open access

Vol 63, No 2 (2013)
Review paper
Published online: 2013-06-10
Get Citation

Economic evaluation of anti-cancer therapies — specifi c approach and challenges of clinical outcomes assessment in oncology

Rafał Zyśk, Maciej Niewada
Nowotwory. Journal of Oncology 2013;63(2):144-156.

open access

Vol 63, No 2 (2013)
Review article
Published online: 2013-06-10

Abstract

The use of QALY (quality adjusted life years) metric to quantify clinical benefi t in oncological settings is limited and
does not correspond with role and importance of QALY introduced with legal changes implemented in Poland in
2012 by Reimbursement Act.
The authors compare diff erent approaches to economic evaluation of anti-cancer therapy in Poland, UK, Canada,
Australia and Germany. The country were considered based on health technology assessment orientated reimbursement
system, specifi c approach applied for anti-cancer or end-of-life therapies and benchmarking in recommendations
issued by Agency of Health Technology Assessment in Poland. Following literature review the key problems
concerning QALY in the evaluation of antineoplastic treatments were defi ned, i.e. EQ-5D is relatively insensitive to
changes in health status of cancer patients, limitations of health utility measurement in cancer, fi xed threshold of
cost-eff ectiveness for all medical technologies regardless of disease specifi city.

Abstract

The use of QALY (quality adjusted life years) metric to quantify clinical benefi t in oncological settings is limited and
does not correspond with role and importance of QALY introduced with legal changes implemented in Poland in
2012 by Reimbursement Act.
The authors compare diff erent approaches to economic evaluation of anti-cancer therapy in Poland, UK, Canada,
Australia and Germany. The country were considered based on health technology assessment orientated reimbursement
system, specifi c approach applied for anti-cancer or end-of-life therapies and benchmarking in recommendations
issued by Agency of Health Technology Assessment in Poland. Following literature review the key problems
concerning QALY in the evaluation of antineoplastic treatments were defi ned, i.e. EQ-5D is relatively insensitive to
changes in health status of cancer patients, limitations of health utility measurement in cancer, fi xed threshold of
cost-eff ectiveness for all medical technologies regardless of disease specifi city.
Get Citation
About this article
Title

Economic evaluation of anti-cancer therapies — specifi c approach and challenges of clinical outcomes assessment in oncology

Journal

Nowotwory. Journal of Oncology

Issue

Vol 63, No 2 (2013)

Article type

Review paper

Pages

144-156

Published online

2013-06-10

Page views

545

Article views/downloads

7385

Bibliographic record

Nowotwory. Journal of Oncology 2013;63(2):144-156.

Authors

Rafał Zyśk
Maciej Niewada

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl